The current national criteria for carotid artery stenting overestimate its efficacy in patients who are symptomatic and at high risk  by Yoshida, Shunsuke et al.

















120The current national criteria for carotid artery
stenting overestimate its efﬁcacy in patients who
are symptomatic and at high risk
Shunsuke Yoshida, MD, MS, Rodney P. Bensley, MD, Julia D. Glaser, BS, Christoph S. Nabzdyk, MD,
Allen D. Hamdan, MD, Mark C. Wyers, MD, Elliot L. Chaikof, MD, and Marc L. Schermerhorn, MD,
Boston, Mass
Background: The Centers for Medicare andMedicaid Services (CMS) have established guidelines that outline patients who
are considered “high risk” for complications after carotid endarterectomy (CEA) for which carotid artery stenting (CAS)
may provide beneﬁt. The validity of these high-risk criteria are yet unproven. In this study, we stratiﬁed patients who
underwent CAS or CEA by CMS high-risk criteria and symptom status and examined their 30-day outcomes.
Methods: A nonrandomized, retrospective cohort study was performed by chart review of all patients undergoing CEA or
CAS from January 1, 2005, to December 31, 2010, at our institution. Demographic data and data pertaining to the
presence or absence of high-risk factors were collected. Patients were stratiﬁed using symptom status and high-risk status
as variables, and 30-day adverse events (stroke, death, myocardial infarction [MI]) were compared.
Results: A total of 271 patients underwent CAS, with 30-day complication rates of stroke (3.0%), death (1.1%), MI
(1.5%), stroke/death (3.7%), and stroke/death/MI (5.2%). A total of 830 patients underwent CEA with 30-day
complication rates of stroke (2.0%), death (0.1%), MI (0.6%), stroke/death (1.9%), and stroke/death/MI (2.7%).
Among symptomatic patients, physiologic high-risk status was associated with increased stroke/death (6 of 42 [14.3%] vs
2 of 74 [2.7%]; P < .01), and anatomic high-risk status was associated with a trend toward increased stroke/death (5 of
31 [16.1%] vs 0 of 20 [0.0%]; P [ .14) in patients who underwent CAS vs CEA. Analysis of asymptomatic patients
showed no differences between the two groups overall, except for a trend toward a higher rate of MI after CAS than after
CEA (3 of 71 [4.2%] vs 0 of 108 [0.0%]; P [ .06) in those who were physiologically at high risk. Among symptomatic
patients who underwent CAS, patients with physiologic and anatomic high-risk factors had a higher rate of stroke/death
than non-high-risk patients (6 of 42 [14.3%] vs 0 of 24 [0.0%] and 5 of 31 [16.1%] vs 0 of 24 [0.0%], respectively; both
P # .05).
Conclusions: Physiologic high-risk status was associated with increased stroke/death, whereas anatomic high-risk
status showed a trend toward increased stroke/death in symptomatic patients undergoing CAS compared with non-
high-risk patients undergoing CAS or physiologically high-risk patients undergoing CEA. Our results suggest that the
current national criteria for CAS overestimate its efﬁcacy in patients who are symptomatic and at high risk. (J Vasc Surg
2013;58:120-7.)Carotid endarterectomy (CEA) has been established as
the gold standard treatment for reducing the risk of stroke
in patients with severe carotid artery stenosis.1-4 More
recently, carotid artery stenting (CAS) has become an
accepted treatment alternative in those considered at highthe Department of Vascular and Endovascular Surgery, Beth Israel
eaconess Medical Center and Harvard Medical School.
work was supported by the National Institutes of Health T32 Harvard-
ngwood Research Training in Vascular Surgery Grant HL007734.
or conﬂict of interest: Dr Schermerhorn is a consultant for Endologix,
ston Scientiﬁc, and Medtronic.
ented at the Plenary Session of the Thirty-eighth Annual Meeting of the
ew England Society for Vascular Surgery, Providence, RI, September
-18, 2011.
rint requests: Marc L. Schermerhorn, MD, 110 Francis St, Ste 5B,
ston, MA 02215 (e-mail: mscherm@bidmc.harvard.edu).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214/$36.00
yright  2013 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2012.12.075risk for complications after CEA. Using data from previous
registries, the Centers for Medicare and Medicaid Services
(CMS) have established and reafﬁrmed guidelines re-
garding the use of CAS as approved reimbursement
coverage criteria.5 These criteria outline patients who are
considered “high-risk” for complications after CEA for
which CAS may provide beneﬁt.
Data from subsequent studies, however, have led to
questions regarding the validity of these high-risk
criteria.6-9 We have found that studies known to date
have stratiﬁed data according to high-risk status or
symptom status, but not both. Therefore, we hypothesized
that a two-tiered stratiﬁcation approach that includes high
risk and symptom status will further delineate a subset of
patients in which CEA or CAS will confer reduced risk.
In an attempt to improve patient selection for the treat-
ment of carotid artery disease, we performed a record
review of all patients who underwent CAS or CEA at our
tertiary medical center from 2005 to 2010, stratiﬁed
them according to CMS high-risk criteria and symptom
status, and examined their 30-day outcomes.
Table I. A, Demographics and comorbidities of patients who underwent carotid artery stenting (CAS) or carotid
endarterectomy (CEA) from January 1, 2005, to December 31, 2010
Variable CAS (n ¼ 271), No. (%) CEA (n ¼ 830), No. (%) P
Male sex 179 (66.1) 470 (56.6) <.01
Symptomatic 85 (31.4) 273 (32.9) .64
High risk, any 172 (63.5) 210 (25.3) <.001
Physiologic high risk 113 (41.7) 182 (21.9) <.001
Age >80 years 47 (17.3) 164 (19.8) .38
CHF (NYHA >III) 13 (4.8) 1 (0.1) <.001
LVEF <30% 21 (7.7) 7 (0.8) <.001
Unstable angina 18 (6.6) 3 (0.4) <.001
MI #30 days 6 (2.2) 1 (0.1) <.001
Hemodialysis 2 (0.7) 11 (1.3) .44
Severe lung diseasea 7 (2.6) 6 (0.7) .01
Contralateral occlusion 23 (8.5) 49 (5.9) .14
Before or after CABG/VR 23 (8.5) 6 (0.7) <.001
Anatomic high risk 82 (30.3) 42 (5.1) <.001
Contralateral laryngeal nerve palsy 1 (0.4) 0 (0.0) .25
Restenosis 60 (22.1) 38 (4.6) <.001
History of neck radiation 14 (5.2) 12 (1.5) <.01
High or low lesion 12 (4.4) 5 (0.6) <.001
Prior neck surgery 18 (6.6) 3 (0.4) <.001
High risk, both 23 (8.5) 14 (1.7) <.001
CABG/VR, Coronary artery bypass graft/valve repair; CHF, congestive heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
NYHA, New York Heart Association.
aDeﬁned as forced expiratory volume in 1 second <30% predicted or home oxygen.
Table I. B, High-risk variables of symptomatic patients who underwent carotid artery stenting (CAS) or carotid
endarterectomy (CEA) from January 1, 2005, to December 31, 2010
Variable CAS (n ¼ 85), No. (%) CEA (n ¼ 273), No. (%) P
Physiologic high risk 42 (49.4) 74 (27.1) <.001
Age >80 years 23 (27.1) 60 (22.0) .38
CHF (NYHA class >III) 2 (2.4) 0 (0.0) .06
LVEF <30% 8 (9.4) 2 (0.7) <.001
Unstable angina 5 (5.9) 0 (0.0) <.001
MI #30 days 2 (2.4) 0 (0.0) .06
Hemodialysis 2 (2.4) 5 (1.8) .67
Severe lung diseasea 1 (1.2) 2 (0.7) .56
Contralateral occlusion 9 (10.6) 16 (5.9) .15
Before or after CABG/VR 3 (3.5) 2 (0.7) .09
Anatomic high risk 31 (36.5) 20 (7.3) <.001
Contralateral laryngeal nerve palsy 0 (0.0) 0 (0.0) >.99
Restenosis 20 (23.5) 10 (3.7) <.001
History of neck radiation 5 (5.9) 10 (3.7) .36
High or low lesion 7 (8.2) 1 (0.4) <.001
Prior neck surgery 8 (9.4) 2 (0.7) <.001
High risk, both 12 (14.1) 5 (1.8) <.001
CABG/VR, Coronary artery bypass graft/valve repair; CHF, congestive heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction;
NYHA, New York Heart Association.
aDeﬁned as forced expiratory volume in 1 second <30% predicted or home oxygen.
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The Beth Israel Deaconess Medical Center Institu-
tional Review Board approved this study.
Patients. Anonrandomized, retrospective cohort study
was performed by record review of all patients under-
going CEA or CAS from January 1, 2005, to December
31, 2010, at our institution. The Vascular Registry,a national carotid procedures registry maintained by the
Society for Vascular Surgery (SVS), was used to identify
all patients undergoing CEA or CAS. In addition, the
hospital database was searched using International Classi-
ﬁcation of Diseases, 9th Revision, Clinical Modiﬁcation
(ICD-9-CM) diagnosis and procedure codes (CAS,
00.63; CEA, 38.12), to identify cases performed before
Table II. Thirty-day adverse events after carotid artery stenting (CAS) versus carotid endarterectomy (CEA) stratiﬁed by
symptom status and high-risk (HR) status
Variable No.
Stroke Death
CAS, No. (%) CEA, No. (%) P CAS, No. (%) CEA, No. (%) P
Symptomatic
Physiologic HR 116 4/42 (9.5) 2/74 (2.7) .19 2/42 (4.8) 0/74 (0) .13
Non-HR 208 0/24 (0) 7/184 (3.8) >.99 0/24 (0) 0/184 (0) >.99
Anatomic HR 51 4/31 (12.9) 0/20 (0) .15 2/31 (6.5) 0/20 (0) .51
Anatomic and physiologic HR 17 1/12 (8.3) 0/5 (0) .51 1/12 (8.3) 0/5 (0) .51
Asymptomatic
Physiologic HR 179 1/71 (1.4) 2/108 (1.9) >.99 0/71 (0) 1/108 (0.9) >.99
Non-HR 511 0/75 (0) 6/436 (1.4) .59 0/75 (0) 0/436 (0) >.99
Anatomic HR 73 0/51 (0) 1/22 (4.6) .30 0/51 (0) 0/22 (0) >.99
Anatomic and physiologic HR 20 0/11 (0) 1/9 (11.1) .26 0/11 (0) 0/9 (0) .26
MI, Myocardial infarction.
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all patients were entered into the SVS Vascular Registry.
Data acquisition. Demographic data and other data
outlined by the CMS guidelines were obtained, including
symptom status, degree of stenosis, speciﬁc physiologic or
anatomic risk factors deemed high risk for CEA per CMS
guidelines,5 and adverse outcomes #30 days of the
procedure. Under CMS guidelines:Patients at high risk for CEA who have symptomatic
carotid artery stenosis >70% are covered for procedures
performed using Food and Drug Administration-
approved CAS systems with embolic protection devices
in facilities approved by CMS to perform CAS proce-
dures. In addition, patients at high risk for CEA with
symptomatic carotid artery stenosis between 50% and
70% and patients at high risk for CEA with asymptomatic
carotid artery stenosis >80% are covered in accordance
with the Category B Investigational Device Exemption
clinical trials regulation (42 CFR 405.201), as a routine
cost under the clinical trials policy.5Physiologic high-risk variables included age >80 years,
New York Heart Association class III congestive heart failure
(CHF), left ventricular ejection fraction <30%, unstable
angina, myocardial infarction (MI) #30 days, forced expira-
tory volume in 1 second <30% of predicted or home oxygen
use, contralateral internal carotid artery occlusion, recent
coronary artery bypass grafting (CABG) or valve repair, and
hemodialysis. Anatomic high-risk factors included contra-
lateral laryngeal nerve palsy, restenosis, history of neck radia-
tion, high or low lesion, and prior neck surgery.
Adverse events, including stroke, death, or MI
#30 days of the procedure, were the primary outcomes.
Strokes excluded transient ischemic attacks (TIAs).
Patients with nonspeciﬁc symptoms or undocumented
symptom status were considered asymptomatic for the
purposes of this study. These patients were known to
have carotid stenoses >80% but without focal symptoms
that would constitute amaurosis fugax, TIA, reversible
ischemic neurologic deﬁcit, or stroke. The record reviewincluded all available notes, including the history and
physical report and review of symptoms. Less than 3% of
patients in the asymptomatic cohort ﬁt this category.
Statistical analysis. We analyzed 30-day adverse
events in patients undergoing CAS vs CEA stratiﬁed by
symptom status (symptomatic or asymptomatic) and high-
risk status (physiologic or anatomic). We then analyzed the
30-day adverse events in symptomatic patients undergoing
CAS or CEA based on physiologic or anatomic high-risk
status vs non-high-risk status. Patient variables were
compared using univariate analysis. Categoric variables
were analyzed using the c2 test and the Fisher exact test
where appropriate. Statistical signiﬁcance was determined
as P < .05. Statistical analyses were performed using
STATA 12 software (StataCorp, College Station, Tex).
RESULTS
The study reviewed 271 CAS patients and 830 CEA
patients. Table I, A and B reports patient demographics,
symptom status, CMS high-risk status, including comor-
bidities that qualify patients into physiologic high-risk
status, and sex. A signiﬁcantly higher proportion of patients
who underwent CAS were at high risk, in overall numbers
or when categorized into physiologic or anatomic status, or
both (63.5%, 41.7%, 30.3%, and 8.5%, respectively),
compared with CEA patients (25.3%, 21.9%, 5.1%, and
1.7%, respectively; P < .01 for all). There was no difference
in the proportion of symptomatic patients who underwent
CEA (32.9%) compared with CAS (31.4%).
The majority of physiologic high-risk factors repre-
sented in the CEA patients were octogenarian status
(19.8%), end-stage renal disease (1.3%), and contralateral
internal carotid artery occlusion (5.9%). Each of the other
comorbidities was present in#1% of the total CEA popula-
tion. This trend was also seen in the CAS patients (octoge-
narian status, 17.3%; contralateral occlusion, 8.5%), but
a wider distribution of comorbidities was found in the
CAS patients. A signiﬁcantly higher percentage of patients
received carotid stents in the settings of signiﬁcant CHF,
poor left ventricular ejection fraction, unstable angina,
MI Stroke/death Stroke/death/MI
CAS, No. (%) CEA, No. (%) P CAS, No. (%) CEA, No. (%) P CAS, No. (%) CEA, No. (%) P
0/42 (0) 1/74 (1.4) >.99 6/42 (14.3) 2/74 (2.7) .01 6/42 (14.3) 3/74 (4.1) .07
0/24 (0) 1/184 (0.5) >.99 0/24 (0) 7/184 (3.8) >.99 0/24 (0) 8/184 (4.4) .60
0/31 (0) 0/20 (0) >.99 5/31 (16.1) 0/20 (0) .14 5/31 (16.1) 0/20 (0) .14
0/12 (0) 0/5 (0) >.99 2/12 (16.7) 0/5 (0) .33 2/12 (16.7) 0/5 (0) .33
3/71 (4.2) 0/108 (0) .06 1/71 (1.4) 2/108 (1.9) >.99 3/71 (4.2) 2/108 (1.9) .39
1/75 (1.3) 3/436 (0.7) .47 0/75 (0) 6/436 (1.4) .59 1/75 (1.3) 9/436 (2.1) >.99
2/51 (3.9) 0/22 (0) >.99 0/51 (0) 1/22 (4.6) .30 1/51 (2) 1/22 (4.6) .52
2/11 (18.2) 0/9 (0) .18 0/11 (0) 1/9 (11.1) .26 2/11 (18.2) 1/9 (11.1) .66
Table II. Continued.
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CABG. There were no signiﬁcant differences in the
percentage of octogenarians, patients with end-stage renal
disease, or patients with contralateral occlusion between
the CAS and CEA patients.
Of the 271 patients who underwent CAS, eight strokes
(3.0%), three deaths (1.1%), and four MIs (1.5%) were
recorded at 30 days. Among the 830 CEA patients,
17 strokes (2.0%), one death (0.1%), and ﬁve MIs (0.6%)
were recorded at 30 days. Ten strokes or deaths (3.7%)
and 13 strokes, deaths, or MIs (4.8%) were counted after
CAS and 17 strokes or deaths (2.0%) and 22 strokes,
deaths, or MIs (2.7%) after CEA. Globally, statistical signif-
icance was only seen with death (CAS: 3 of 271 vs CEA:
1 of 830; P ¼ .05) and stroke, death, or MI (CAS: 14 of
271 vs CEA: 22 of 830; P ¼ .04).
Stratiﬁed analysis based on symptom status and
high-risk status. Differences in outcome betweenCAS and
CEA were measured after stratifying the data by symptom
status and high-risk status (Table II). Among the symp-
tomatic patients, physiologic high-risk status was associated
with increased stroke/death (6 of 42 [14.3%] vs 2 of 74
[2.7%]; P< .01) in patients who underwent CAS compared
with CEA, with a trend for higher stroke (4 of 42 [9.5%] vs 2
of 74 [2.7%]; P ¼ .19) and stroke/death/MI rates (6 of 42
[14.3%] vs 3 of 74 [4.2%]; P ¼ .07) after CAS. Of the 42
symptomatic, physiologic high-risk patients who underwent
CAS, 23 were octogenarians and accounted for 3 of the 6
strokes/deaths. There were no differences in adverse events
among the symptomatic, non-high-risk patients undergoing
CAS vs CEA. Symptomatic, anatomic high-risk patients
showed a trend toward higher rates of stroke (4 of 31
[12.9%] vs 0 of 20 [0.0%]; P ¼ .15) and stroke/death (5 of
31 [16.1%] vs 0 of 20 [0.0%]; P ¼ .14) after CAS.
Asymptomatic patients had a trend toward a higher
rate of MI after CAS than after CEA (3 of 71 [4.2%]
vs 0 of 108 [0.0%]; P ¼ .06) if they were physiologically
at high risk. No adverse events were noted at 30 days
among non-high-risk or anatomically high-risk asymptom-
atic patients. Overall, stroke, death, and stroke/deathrates were low in asymptomatic patients after CAS,
whereas MI rates were low in asymptomatic patients after
CEA.
Among symptomatic patients who underwent CAS
(Table III), the rate of stroke/death among physiologic
high-risk and anatomic high-risk patients was higher (6
of 42 [14.3%] vs 0 of 24 [0.0%]; P ¼ .05) than in their
non-high-risk counterparts (5 of 31 [16.1%] vs 0 of 24
[0.0%]; P ¼ .04). There were no MIs in symptomatic
patients after CAS. Furthermore, symptomatic non-high-
risk patients were complication-free during the 30-day
investigative window. In comparison, symptomatic patients
who underwent CEA had no differences in 30-day adverse
events when comparing risk status.
There were no signiﬁcant differences among asymp-
tomatic patients who underwent CAS or CEA when
comparing physiologic high-risk or anatomic high-risk
patients vs non-high-risk patients (Table IV). The lone
exception was the observation of one death among asymp-
tomatic, physiologically high-risk patients that led to
a statistically signiﬁcant result (1 of 108 [0.9%] vs 0 of
436 [0.0%]; P ¼ .04).
The inﬂuence of octogenarian status on outcome.
Of the 271 patients who underwent CAS, 47 were aged
>80 years and 224 were <80 years. Rates of stroke/death
were similar (3 of 47 [6.4%] vs 7 of 224 [3.1%]; P ¼ .28).
Of the 830 patients who underwent CEA, 164 were aged
>80 years and 668 were <80 years; again, rates of stroke/
death were similar (5 of 164 [3.1%] vs 12 of 668 [1.8%];
P ¼ .31).
Of the physiologically high-risk patients aged <80, 66
underwent CAS and 48 underwent CEA. Among this pop-
ulation, there was no difference in stroke (4.6% [3 of 66] vs
0% [0 of 48]; P ¼ .26), MI (3.0% [2 of 66] vs 0% [0 of 48];
P¼ .51), death (1.5% [1 of 66] vs 0% [0 of 48]; P> .99), or
stroke/death (6.1% [4 of 66] vs 0% [0 of 48]; P ¼ .14).
However, a statistical difference was detected in stroke/
death/MI (9.1% [6 of 66] vs 0% [0 of 48]; P¼ .04). Further
stratiﬁcation to include symptom status yielded 19 symp-
tomatic, physiologically high-risk patients aged <80 years
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were no differences in 30-day outcomes in CAS vs CEA
for stroke (2 of 19 [10.5%] vs 0 of 16 [0.0%]; P ¼ .49),
MIs (none), death (1 of 19 [5.3%] vs 0 of 16 [0.0%]; P >
.99), stroke/death (3 of 19 [15.8%] vs 0 of 16 [0.0%];
P ¼ .23), and stroke/death/MI (3 of 19 [15.8%] vs 0 of
16 [0.0%]; P ¼ .23).
DISCUSSION
Our study has two important ﬁndings. First, signiﬁ-
cantly higher rates of stroke/death were observed in phys-
iologically high-risk symptomatic patients after CAS than
after CEA. Second, an increased risk of stroke/death was
observed in physiologically high-risk symptomatic patients
compared with non-high-risk symptomatic patients under-
going CAS, but this was not observed in patients under-
going CEA. Symptomatic patients are thought to incur
higher rates of morbidity and mortality after CAS than after
CEA.10-12 Our results suggest that among symptomatic
patients, those who are physiologically at high risk may
have the highest risk of 30-day adverse events after CAS.
The CMS physiologic high-risk criteria, based on the
criteria ﬁrst published in the Stenting and Angioplasty
with Protection in Patients at High Risk for Endarterec-
tomy (SAPPHIRE) trial,13 are intended to identify patients
who are at increased risk for complications with CEA.
These patients are considered better suited for an endovas-
cular procedure to avoid potential perioperative risks asso-
ciated with open surgery. Our analysis suggests that the
current CMS physiologic high-risk criteria may not identify
the population best suited for CAS.
We observed a trend toward higher incidences of
stroke/death in the symptomatic, anatomic high-risk
patients who underwent CAS compared with CEA, but
statistical signiﬁcance was not reached. Further study with
greater power is indicated to determine whether symptom-
atic, anatomic high-risk patients are at greater risk for
30-day adverse events after CAS because surgeons would
be more likely to undertake redo surgery if this were clearly
demonstrated.
According to our data, differences in outcome may
be tied to high-risk status and symptom status, and pro-
spective data are needed to provide evidence-based recom-
mendations for patients. Previous randomized control trials
have stratiﬁed patients according to symptom status or
high-risk status, but not both. The Stent-Protected Angio-
plasty vs Carotid Endarterectomy (SPACE) trial random-
ized 1183 symptomatic patients.11 The study excluded
patients with restenosis and previous radiation. No other
risk status restrictions were instituted; however, some
high-risk patients were likely excluded under the criterion
of severe concomitant disease with poor prognosis, as
determined by individual physicians. The results showed
no differences in outcomes of stroke/death between CAS
(6.84%) and CEA (6.34%) at 30 days, yet failed to prove
noninferiority of carotid stents.
The Endarterectomy Vs Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis (EVA-3S) studyalso studied symptomatic patients and is known for prema-
turely stopping the trial early for futility and safety
concerns.10 The 30-day stroke/death rate for the CAS
arm was 9.6% compared with 3.9% in the CEA arm at
the conclusion of the study. High-risk status was not
accounted for in the EVA-3S trial, although this study
excluded patients with unstable angina, restenosis, and
need for additional surgical procedures #30 days. Only
12 CAS deployments were required for operators to be
included in the study compared with a median number
of 64 in SAPPHIRE, and many have criticized this as
bias favoring CEA.
The International Carotid Stenting Study (ICSS)
randomized1649 symptomatic, low-risk patients.14Accord-
ing to the study protocol, patients with restenosis, planned
CABG, and those medically not ﬁt or anatomically not suit-
able for surgery were excluded from the study. The trial
concluded with 30-day stroke/death and stroke/death/
MI rates that favored CEA, at 7.4% vs 3.4% (P ¼ .0004)
and 7.4% vs 4.0% (P ¼ .003), respectively.
The Carotid Revascularization Endarterectomy vs
Stent Trial (CREST) randomized 2502 patients, 52% of
whom were symptomatic.15 Patients were mostly not at
high risk because the study excluded patients with all major
high-risk criteria as set by CMS except age >80 years and
contralateral internal carotid artery occlusion.16 There
were no signiﬁcant differences in rates of ipsilateral stroke,
MI, or death during the 4 years after CAS or CEA (7.2% vs
6.8%; P ¼ .51). When the 4-year rate of ipsilateral stroke or
death was compared, the results favored CEA (6.4% vs
4.7%; P ¼ .03). Periprocedural strokes were more common
after CAS (4.1% vs 2.3%; P ¼ .01), whereas periprocedural
MIs were more common after CEA (1.1% vs 2.3%; P ¼
.03).15 Later analysis showed stroke or death rates to be
lower among symptomatic patients who underwent CEA
(4.4% vs 2.3%; P ¼ .005).12 Overall incidences of 30-day
adverse events were low compared with previous random-
ized control trials.12,15 Low event rates in CREST may be
explained somewhat by the fact that most patients were
“low risk.”
The SAPPHIRE trial evaluated 334 high-risk
patients.13 The high-risk criteria were those incorporated
by CMS and, therefore, similar to the criteria used for
this study. Results of 30-day adverse events favored CAS
when comparing the incidences of stroke/death/MI (7
of 159 [4.4%] vs 15 of 151 [9.9%]; P < .04). The rates
of MI had a strong inﬂuence on outcome (3 of 159
[1.9%] for CAS and 10 of 151 [6.6%] for CEA), and no
differences were seen in outcomes of stroke, death, or
stroke/death. The SAPPHIRE trial is known as the ﬁrst
trial to show noninferiority of CAS compared with CEA
in the high-risk population. However, the patients were
not stratiﬁed by symptom status, and >70% were asymp-
tomatic. The subsequent SAPPHIRE registry data showed
that patients with physiologic high-risk factors had an
increased risk of 30-day adverse events compared with
patients with anatomic high-risk factors (4.9% vs 2.8%;
P ¼ .0306).17 Our 30-day adverse event rates for CAS
Table III. Thirty-day adverse events in symptomatic patients undergoing carotid artery stenting (CAS) or carotid






PNo. (%) No. (%) No. (%) No. (%)
CAS 42 24 31 24
Stroke 4 (9.5) 0 (0) .12 4 (12.9) 0 (0) .07
Death 2 (4.8) 0 (0) .28 2 (6.5) 0 (0) .20
MI 0 (0.0) 0 (0) >.99 0 (0.0) 0 (0) >.99
Stroke/death 6 (14.3) 0 (0) .05 5 (16.1) 0 (0) .04
Stroke/death/MI 6 (14.3) 0 (0) .05 5 (16.1) 0 (0) .04
CEA, No. 74 184 20 184
Stroke 2 (2.7) 74 (3.8) .66 0 (0) 7 (3.8) .37
Death 0 (0.0) 0 (0) >.99 0 (0) 0 (0) >.99
MI 1 (1.4) 1 (0.5) .50 0 (0) 1 (0.5) .74
Stroke/death 2 (2.7) 7 (3.8) .66 0 (0) 7 (3.8) .37
Stroke/death/MI 3 (4.1) 8 (4.3) .92 0 (0) 8 (4.3) .34
MI, Myocardial infarction.
Table IV. Thirty-day adverse events in asymptomatic patients undergoing carotid artery stenting (CAS) or carotid






PNo. (%) No. (%) No. (%) No. (%)
CAS 71 75 51 75
Stroke 1 (1.4) 0 (0.0) .30 0 (0.0) 0 (0.0) >.99
Death 0 (0.0) 0 (0.0) >.99 0 (0.0) 0 (0.0) >.99
MI 3 (4.2) 1 (1.3) .28 2 (3.9) 1 (1.3) .35
Stroke/death 1 (1.4) 0 (0.0) .30 0 (0.0) 0 (0.0) >.99
Stroke/death/MI 4 (5.6) 1 (1.3) .15 2 (3.9) 1 (1.3) .35
CEA 108 436 22 436
Stroke 2 (1.9) 6 (1.4) .71 1 (4.6) 6 (1.4) .24
Death 1 (0.9) 0 (0.0) .04 0 (0.0) 0 (0.0) >.99
MI 0 (0.0) 3 (0.7) .39 0 (0.0) 3 (0.7) .70
Stroke/death 2 (1.9) 6 (1.4) .71 1 (4.6) 6 (1.4) .24
Stroke/death/MI 2 (1.9) 9 (2.1) .88 1 (4.6) 9 (2.1) .44
MI, Myocardial infarction.
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were similar to rates reported in SAPPHIRE (3.1%, 0.6%,
1.9%, and 4.4%, respectively); however, CEA results from
their trial (stroke, 3.3%; death, 2.0%; MI, 6.6%; and
combined, 9.9%) showed much higher rates of complica-
tions compared with our data (stroke, 2.0%; death, 0.1%;
MI, 0.6%; combined, 2.7%).
Interestingly, non-high-risk patients and asymptomatic
patients who underwent CAS were not at increased risk of
30-day complications compared with CEA. The CREST
investigators also found no differences in periprocedural
adverse events among asymptomatic patients who under-
went CAS vs CEA.12 The current focus is to allow CAS
in symptomatic or high-risk patients; instead, CAS may
be a reasonable alternative in asymptomatic or non-high-
risk patients.The SVS Vascular Registry study8 compared symptom-
atic and asymptomatic patients undergoing CAS and found
increased stroke/death/MI rates in symptomatic patients.
This study further compared data between CEA and CAS
but did not stratify the data according to high-risk status.
Others have performed retrospective studies to question
the validity of the high-risk criteria in patients who under-
went CAS9 or CEA,18,19 but perioperative stroke/death
rates were comparable among high-risk and non-high-risk
cohorts. The key difference between this report and prior
studies is the analysis of patient groups stratiﬁed by
symptom as well as high-risk status. Furthermore, high-
risk status was stratiﬁed by physiologic vs anatomic high-
risk factors.
Advanced age is thought to incur worse outcomes in
those who undergo CAS, with octogenarians being the
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toward worse outcomes in octogenarians who underwent
CAS compared with CEA (odds ratio, 2.06); however,
these results were not statistically signiﬁcant (P ¼ .38).
Octogenarians comprised 91% (164 of 182) of those with
physiologic high-risk designations in the CEA group and
41.6% (47 of 113) of those in the CAS group in this study.
We examined the data among physiologic high-risk
patients aged <80 years and found no differences in
stroke/death rates (4 of 66 vs 0 of 48; P ¼ .51) but
stroke/death/MI rates were increased in those who under-
went CAS compared with CEA (6 of 66 vs 0 of 48; P ¼
.04). Among patients aged <80 years with physiologic
high-risk status and symptoms, no statistically signiﬁcant
results were achieved between CAS and CEA in stroke/
death or stroke/death/MI (3 of 19 vs 0 of 16; P ¼ .23).
Trends toward better outcomes after CEA were evident,
and further evaluation with larger numbers is warranted.
Among patients aged <80 years, the diversity of phys-
iologic high-risk factors varied between the two groups. Of
the 48 patients in the CEA group, 29 had contralateral
occlusion and 46 (95.8%) had just one high-risk factor.
The CAS cohort had more patients with multiple risk
factors (20 of 66 [30.3%]) and more patients with high-
risk factors that are likely to be more prohibitive of an
operation such as CHF and unstable angina. The experi-
mental and selective nature of CAS inherently leads to
a patient population that is at higher risk.
Retrospective studies that analyze nonrandomized data
are inherently biased against CAS because greater percent-
ages of high-risk, symptomatic patients are included in the
CAS group secondary to CMS reimbursement criteria and
patient selection by the provider. This imbalance in patient
cohorts makes a fair comparison of outcomes difﬁcult to
perform. Our group previously published an analysis of
Nationwide Inpatient Sample data, stratifying patient data
according to high-risk status, and found CAS was associated
with a higher incidence of stroke, death, and stroke/death in
the medically high-risk population.7 However, database
limitations led to the inability to (1) distinguish periopera-
tive from preoperative stroke and (2) discern the severity
of comorbid medical conditions, leading to potentially
inaccurate assignment of high-risk status. Furthermore,
the analysis was limited to physiologic high-risk status and
immediate in-hospital perioperative complication rates.
This studywas aimed at overcoming these limitations by per-
forming a record review. We were able to show CAS was
associated with worse 30-day outcomes in physiologic
high-risk, symptomatic patients. Our results suggest the
need for future trials to include this stratiﬁcation. In our
study, we did not detect differences in adverse event rates
between CAS and CEA in the asymptomatic and non-
high-risk patient populations; however, stratiﬁcation of
data yielded low event rates that increased the chances of
a type II error. Larger sample sizes are needed to overcome
this limitation.
Finally, we acknowledge that the sample size among
high-risk patients was too small to compare the effects ofeach risk factor and its effect on 30-day morbidity or
mortality rates. Previous research has demonstrated that
a minimum of ﬁve events needs to be present for each inde-
pendent variable included in a multivariable model.21 This
type of analysis could be performed, albeit at the risk of
overloading the model and thus making the results highly
unreliable. Because of this limitation, we determined it
was best to limit our analysis to its current form. Continued
collection of data will improve our ability to detect differ-
ences among individual risk factors in the future. Analysis
using a large database to determine the effects of individual
risk factors has been performed previously for patients who
underwent CEA.22 Whether the same risk factors hold true
for those undergoing CAS is unknown. Reﬁnement of data
collection and analysis methods will improve our patient
selection for CAS, CEA, or medical management.
CONCLUSIONS
Physiologic high-risk status was associated with
increased stroke/death in symptomatic patients under-
going CAS compared with non-high-risk patients under-
going CAS or physiologic high-risk patients undergoing
CEA. Anatomic high-risk status also showed increased
rates of stroke/death in symptomatic patients, although
statistical signiﬁcance was not reached. Current selection
criteria for CAS vs CEA may be inappropriate. Physiologic
high-risk, symptomatic patients, as deﬁned by the current
CMS criteria for CAS reimbursement, may be better suited
for CEA than CAS. CAS may be a reasonable alternative to
CEA in symptomatic patients who are not at high risk.
Future comparative analyses of CEA vs CAS should be
stratiﬁed according to physiologic high-risk status and
symptom status to overcome bias in patient selection.
Further work and a greater number of patients are needed
to identify appropriate patients for CAS, CEA, or medical
management.
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